References
- Mitsumoto H. Amyotrophic lateral sclerosis. Philadelphia (PA): FA Davis Company; 1998.
- Bello-Haas VD. Physical therapy for individuals with amyotrophic lateral sclerosis: current insights. Degener Neurol Neuromuscul Dis. 2018;8:45–54.
- Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–28.
- Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225–38.
- Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, Centers for Disease Control and Prevention (CDC), et al. Prevalence of amyotrophic lateral sclerosis – United States. MMWR Suppl. 2014;63:1–2011.
- Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, et al. Prevalence of amyotrophic lateral sclerosis – United States, 2012–2013. MMWR Surveill Summ. 2016;65:1–12.
- Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of ayotrophic lateral sclerosis – United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:1285–9.
- Mehta P, Kaye W, Raymond J, Wu R, Larson T, Punjani R, et al. Prevalence of amyotrophic lateral sclerosis – United States, 2014. MMWR Morb Mortal Wkly Rep. 2018;67:216–8.
- Mehta P, Raymond J, Punjani R, Larson T, Bove F, Kaye W, et al. Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016. Amyotroph Lateral Scler Frontotemporal Degener. 2021;0:1–6.
- Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study. Neurology 2009;72:1640–5.
- Bhandari R, Kuhad A, Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc). 2018;54:349–60.
- Dharmadasa T, Kiernan MC. Riluzole, disease stage and survival in ALS. Lancet Neurol. 2018;17:385–6.
- Andrew AS, Chen CY, Caller TA, Tandan R, Henegan PL, Jackson BP, et al. Toenail mercury levels are associated with amyotrophic lateral sclerosis risk. Muscle Nerve. 2018;58:36–41.
- Bradley WG, Borenstein AR, Nelson LM, Codd GA, Rosen BH, Stommel EW, et al. Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases? Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:325–33.
- Capozzella A, Sacco C, Chighine A, Loreti B, Scala B, Casale T, et al. Work related etiology of amyotrophic lateral sclerosis (ALS): a meta-analysis. Ann Ig. 2014;26:456–72.
- Cox PA, Richer R, Metcalf JS, Banack SA, Codd GA, Bradley WG. Cyanobacteria and BMAA exposure from desert dust: a possible link to sporadic ALS among Gulf War veterans. Amyotroph Lateral Scler. 2009;10(Suppl 2):109–17.
- Goutman SA, Boss J, Patterson A, Mukherjee B, Batterman S, Feldman EL. High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:907–12.
- Weisskopf MG, Cudkowicz ME, Johnson N. Military service and amyotrophic lateral sclerosis in a population-based cohort. Epidemiology 2015;26:831–8.
- Bozzoni V, Pansarasa O, Diamanti L, Nosari G, Cereda C, Ceroni M. Amyotrophic lateral sclerosis and environmental factors. Funct Neurol. 2016;31:7–19.
- Eisen A. Amyotrophic lateral sclerosis is a multifactorial disease. Muscle Nerve. 1995;18:741–52.
- Su FC, Goutman SA, Chernyak S, Mukherjee B, Callaghan BC, Batterman S, et al. Association of environmental toxins with amyotrophic lateral sclerosis. JAMA Neurol. 2016;73:803–11.
- US Public Health Service. ALS Registry Act. Washington, DC: 110th Congress; 2008.
- Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, Weekly Tables of Infectious Disease Data. Atlanta, GA. Available from: https://www.cdc.gov/nndss/infectious-tables.html.
- Massachusetts Department of Public Health. Massachusetts ALS Registry. Available from: https://www.mass.gov/als-registry.
- Kaye WE, Sanchez M, Wu J. Feasibility of creating a National ALS Registry using administrative data in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:433–9.
- U.S. Census Bureau. National Population by Characteristics: 2010–2019. Available from: https://www.census.gov/data/tables/time-series/demo/popest/2010s-national-detail.html.
- Hook EB, Regal RR. The value of capture–recapture methods even for apparent exhaustive surveys. The need for adjustment for source of ascertainment intersection in attempted complete prevalence studies. Am J Epidemiol. 1992;135:1060–7.
- Zhou S, Qian S, Li X, Zheng L, Chang W, Wang L. Using the capture-recapture method to estimate the incidence of amyotrophic lateral sclerosis in Beijing, China. Neuroepidemiology 2018;50:29–34.
- Huisman MH, de Jong SW, van Doormaal PT, Weinreich SS, Schelhaas HJ, van der Kooi AJ, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry. 2011;82:1165–70.
- Rosenbohm A, Peter RS, Erhardt S, Lulé D, Rothenbacher D, Ludolph AC, ALS Registry Study Group, et al. Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J Neurol. 2017;264:749–57.
- Nelson LM, Topol B, Kaye W, Raymond J, Horton DK, Mehta P, et al. Evaluation of the completeness of ALS Case Ascertainment in the U.S. National ALS Registry: application of the capture-recapture method. Neuroepidemiology 2021;0:1–11.
- Medicare Resources. Understanding your Medicare Plan Options. Accessed November 12, 2020. Available from: https://www.medicareresources.org/medicare-benefits.
- ALS Association. VA Provides Benefits to Veterans with ALS and Families. Accessed November 12, 2020. Available from: http://web.alsa.org/site/PageServer?pagename=va_provides_benefits.
- Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. 2009;65:591–8.
- King M, Bearman P. Diagnostic change and the increased prevalence of autism. Int J Epidemiol. 2009;38:1224–34.
- Kaye WE, Wagner L, Wu R, Mehta P. Evaluating the completeness of the national ALS registry, United States. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:112–7.
- Horton DK, Graham S, Punjani R, Wilt G, Kaye W, Maginnis K, et al. A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:126–33.
- Hogden A, Foley G, Henderson RD, James N, Aoun SM. Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach. J Multidiscip Healthc. 2017;10:205–15.
- Majmudar S, Wu J, Paganoni S. Rehabilitation in amyotrophic lateral sclerosis: why it matters. Muscle Nerve. 2014;50:4–13.
- Soriani MH, Desnuelle C. Care management in amyotrophic lateral sclerosis. Rev Neurol (Paris). 2017;173:288–99.
- Insurance Information Institute. Facts + Statistics: Industry Overview. Available from: https://www.iii.org/fact-statistic/facts-statistics-industry-overview.
- ALS Association. FYI: A Professional’s Guide to Assisting Families with Obtaining Government Benefits. Available from: https://www.als.org/navigating-als/resources/fyi-professionals-guide-assisting-families-obtaining-government-benefits.
- IQVIA Human Data Science. IQVIA PharMetrics Plus. Accessed November 12, 2020. Available from: https://www.iqvia.com.
- Optum Health Services Innovation Company. Accessed November 12, 2020. Available from: https://www.optum.com.
- Truven Marketscan Research Data. Accessed November 12, 2020. Available from: https://marketscan.truvenhealth.com/marketscanportal/.
- Irish Motor Neurone Disease Register. Available from: https://www.hiqa.ie/areas-we-work/health-information/data-collections/irish-motor-neurone-disease-register.
- Gomeni R, Fava M, Pooled Resource Open-Access ALS Clinical Trials Consortium. Pooled Resource Open-Access ALSCTC. Amyotrophic lateral sclerosis disease progression model. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:119–29.
- Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7:1103–16.
- Centers for Disease Control and Prevention. HIV Surveillance Report. Accessed November 12, 2020. Available from: https://www.cdc.gov/hiv/statistics/overview/index.html.
- Yelk Woodruff RS, Pratt RH, Armstrong LR. The US National Tuberculosis Surveillance System: a descriptive assessment of the completeness and consistency of data reported from 2008 to 2012. JMIR Public Health Surveill. 2015;1:e15.